- Home
- IOVA vs LEO Comparison
IOVA vs LEO Comparison
Compare IOVA & LEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- LEO
- Stock Information
- Founded
- IOVA 2007
- LEO 1987
- Country
- IOVA United States
- LEO United States
- Employees
- IOVA N/A
- LEO N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- LEO Trusts Except Educational Religious and Charitable
- Sector
- IOVA Health Care
- LEO Finance
- Exchange
- IOVA Nasdaq
- LEO Nasdaq
- Market Cap
- IOVA 771.4M
- LEO 363.8M
- IPO Year
- IOVA N/A
- LEO N/A
- Fundamental
- Price
- IOVA $1.71
- LEO $5.87
- Analyst Decision
- IOVA Buy
- LEO
- Analyst Count
- IOVA 10
- LEO 0
- Target Price
- IOVA $12.22
- LEO N/A
- AVG Volume (30 Days)
- IOVA 11.8M
- LEO 200.2K
- Earning Date
- IOVA 08-07-2025
- LEO 01-01-0001
- Dividend Yield
- IOVA N/A
- LEO 4.01%
- EPS Growth
- IOVA N/A
- LEO N/A
- EPS
- IOVA N/A
- LEO 0.04
- Revenue
- IOVA $212,679,000.00
- LEO N/A
- Revenue This Year
- IOVA $86.62
- LEO N/A
- Revenue Next Year
- IOVA $69.95
- LEO N/A
- P/E Ratio
- IOVA N/A
- LEO $152.00
- Revenue Growth
- IOVA 11070.12
- LEO N/A
- 52 Week Low
- IOVA $1.64
- LEO $4.98
- 52 Week High
- IOVA $12.51
- LEO $6.50
- Technical
- Relative Strength Index (RSI)
- IOVA 36.89
- LEO 46.67
- Support Level
- IOVA $1.95
- LEO $5.77
- Resistance Level
- IOVA $2.47
- LEO $5.82
- Average True Range (ATR)
- IOVA 0.16
- LEO 0.03
- MACD
- IOVA -0.00
- LEO 0.00
- Stochastic Oscillator
- IOVA 6.41
- LEO 37.50
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products are Equity and Fixed Income Mutual Funds, Retail Money Market Funds, Government/Treasury Money Market Funds, Institutional Money Market Funds, and others. BNY Mellon and its affiliates, including BNYM Investment Adviser, INA and others involved in the management, sales, investment activities, business operations or distribution of the Fund, are engaged in businesses and have interests other than that of managing the Fund.